Pluristem Therapeutics

335 articles with Pluristem Therapeutics

• Pluristem Therapeutics Demonstrates the Potential of Its PLX Cells to Treat Crohn's Disease and Ulcerative Colitis

  5/28/2008

• Pluristem Therapeutics to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference

  5/19/2008

• Pluristem Therapeutics to be Featured on RedChip's Real Radio(TM) Show Broadcast

  5/15/2008

• Pluristem Therapeutics Announces Removal of Restrictive Legends on Shares of Restricted Common Stock According to May 2007 Private Placement Agreement

  5/15/2008

• FDA and the Paul Ehrlich Institute (Germany) Approve Pluristem Therapeutics's Regulatory Submissions in Support of a Phase I/II Clinical Trial Utilizing PLX-PAD for Peripheral Artery Disease

  5/6/2008

• Pluristem Therapeutics to Present at LD MICRO Conference April 29, 2008

  4/28/2008

• Pluristem Therapeutics to Present to President Bush and Others at the First Annual Israeli Presidential Conference

  4/23/2008

• Pluristem Therapeutics's PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model

  4/14/2008

• Pluristem Therapeutics's Second Pre-Clinical Study in Ischemic Stroke Shows Statistically Significant Advantages in Functional and Anatomical Recovery

  4/7/2008

• Pluristem Therapeutics Submits Pre-IND Application in Germany to Initiate Clinical Trials of PLX-PAD for Peripheral Artery Disease

  3/4/2008

• Pluristem Therapeutics to Present its Clinical Trial Plans at the Roth Capital Partners 20th Annual OC Growth Stock Conference

  2/19/2008

• Pluristem Therapeutics Announces Second Clinical Indication Revascularization Effect After PLX-PAD Therapy

  1/8/2008

• Pluristem Therapeutics Approved for Listing on NASDAQ Capital Market

  12/7/2007

• Pluristem Therapeutics Approved for Listing on NASDAQ Capital Market

  12/6/2007

• Pluristem Therapeutics' Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders

  11/27/2007